Who Liquid Cartilage injections are suitable for

The practical dividing line is stated once up front: ChondroFiller® (often discussed as “Liquid Cartilage”) is described in the clinical literature as a treatment aimed at a contained (focal) cartilage defect in an otherwise “saveable” joint, not for whole‑joint, end‑stage arthritis where replacement is usually the more realistic pathway.

In published studies, ChondroFiller is used as a scaffold material placed into a defined defect (most commonly described during arthroscopy) with the intent of supporting cartilage repair.

In practice, suitability tends to be discussed in terms of a localised defect (often described on imaging or arthroscopy as a limited area of high‑grade cartilage damage) with the rest of the joint structure reasonably preserved. Joints with the most direct published clinical data in this packet include the knee and hip, with additional early experience in other joints (for example, the ankle and wrist) reported in smaller studies.

A simple rule-of-thumb based on what tends to do poorly in published hip series:

• “Green flags”: a single, well‑defined defect; symptoms that match a focal lesion; joint space and mechanics that still look salvageable on imaging.
• “Red flags”: diffuse, advanced osteoarthritis, such as hips with established Tönnis grade 2–3 changes, where outcomes with ChondroFiller have been reported as poor and where other joint‑preservation strategies or replacement are more often considered.

Shoulder catching and whether an injection alone can help

A shoulder that “catches” or “locks” often feels different from a shoulder that is simply sore or stiff. Mechanical symptoms are commonly described after a specific injury (for example a fall onto the arm) or alongside early wear-and-tear, and they raise the possibility that something is physically snagging as the joint moves. In practical terms, that “something” is usually a piece of tissue that moves when it shouldn’t, or a fragment that moves when it shouldn’t be there at all.

Common mechanical culprits in the shoulder include:

• A loose body (a small fragment of cartilage or bone) intermittently getting trapped in the joint.
• An unstable cartilage flap at the edge of a focal defect, which can fold and “catch” during overhead movement.
• A labral tear (the rim of cartilage around the socket) acting like a doorstop in certain positions.

ChondroFiller (Liquid Cartilage) is described in the wider cartilage-repair literature as a defect-targeting scaffold approach that relies on accurate placement into a contained lesion and appropriate lesion preparation/edge stability in operative protocols. That design intent matters for the “catching” question: a scaffold is not intended to “wash away” a flap or remove a loose body.

For that reason, a simple blind intra-articular injection (of any substance) is very unlikely to reliably “un-catch” a shoulder if the main problem is a true mechanical block from a loose body, unstable flap, or a labral tear. Where mechanical obstruction is suspected, keyhole (arthroscopic) assessment and treatment is often the step used to remove or stabilise the catching tissue and to prepare any focal defect for a repair strategy.

A realistic pathway usually starts with a structured clinical assessment and high-quality imaging (often MRI), sometimes using a diagnostic injection to separate pain-driven symptoms from a mechanical block. If “catching” persists and examination findings continue to suggest a physical obstruction, arthroscopy may be discussed to address the cause; where a well-defined focal defect remains afterwards, a scaffold approach can then be considered in the right pattern of damage.

Liquid Cartilage or MACI for medium knee defects

How the procedures differ (one stage vs two)

MACI/ACI are cell-based cartilage repairs. In plain terms, they are commonly described as two-stage procedures: cartilage is harvested, the cells are expanded in a laboratory, and then the repair is performed in a subsequent procedure where cultured cells are implanted on a membrane or within a scaffold.

ChondroFiller-based “Liquid Cartilage” approaches are different in kind: they are described as single-stage, cell-free scaffold techniques intended to support repair within a defined focal defect, and published series commonly describe arthroscopic placement into a prepared lesion.

Who MACI/ACI is typically reserved for

Across knee-cartilage literature, MACI/ACI are most often discussed for medium-to-large focal defects (commonly framed around the ~2–10 cm² range), particularly in patients where long-term durability is a priority and simpler marrow-stimulation options may be less reliable over time.

What it tends to mean for rehabilitation and time off work

Because MACI/ACI involves staged surgery and cell processing, it is typically a bigger overall commitment and often comes with a more structured rehabilitation phase than a single-stage scaffold-only approach (exact restrictions vary by lesion size, location and concomitant procedures).

What the evidence shows (and what it doesn’t)

For cell-based ACI techniques, the evidence base includes large prospective trial datasets. For example, a hydrogel-based ACI phase III trial in 100 patients with 4–12 cm² defects reported 93% KOOS responders at 2 years with a mean KOOS improvement of about 42 points and a mean MOCART score of 80.

For ChondroFiller, published knee data are earlier-stage: for example, a 17-patient arthroscopic series reported statistically significant improvements in Lysholm and IKDC scores between baseline and 3, 6 and 12 months, with no major complications over 12 months.

However, there are no published randomised head-to-head trials in this packet directly comparing ChondroFiller-based scaffold approaches with MACI/ACI for medium-sized knee defects, so the two pathways cannot yet be ranked by like-for-like comparative evidence.

A practical way to weigh the options

In day-to-day terms, the trade-off is often framed around invasiveness versus evidence depth: MACI/ACI is more invasive and resource-intensive, but supported by broader mid- to long-term datasets in appropriately selected lesions; scaffold-only approaches such as ChondroFiller aim to reduce procedural burden, with encouraging short- to mid-term series but a shorter and less comparative evidence trail so far.

What outcomes and risks look like in knee and hip

Numbers in the published ChondroFiller® (“Liquid Cartilage”) literature for the knee and hip are generally encouraging in the right pattern of damage, but they come mostly from small cohorts and—importantly—many of the best-described studies used arthroscopic placement into a prepared defect.

Knee: symptom scores and what they usually mean

One single-centre knee series followed 17 patients treated arthroscopically with ChondroFiller Liquid® and tracked outcomes to 12 months. In that group, both Lysholm and IKDC scores improved significantly from baseline at 3, 6 and 12 months (p < 0.05), with the authors reporting no major complications over the year of follow-up. In practical terms, those score changes are typically interpreted as improvements in day-to-day knee function such as walking distance, stairs, swelling and confidence with activity, rather than a guarantee of returning to impact sport.

Safety signals and what remains uncertain

In published knee cohorts such as the 17-patient/12‑month series, major short-term complications have not been prominent. Two points remain clear from the current evidence base: (1) outcomes have been best reported in focal defects, not whole-joint arthritis; and (2) longer-term durability and reoperation rates are still less well characterised than they are for established surgical options.

Hip: medium-term outcomes (and who doesn’t do well)

The most informative hip data in this packet include a prospective cohort of 26 adults with femoroacetabular impingement and acetabular cartilage lesions >2 cm², treated during hip arthroscopy with ChondroFiller gel. At 3–5 years, outcomes were available for 21/26 patients; 17/21 were rated good or excellent, while 2 patients progressed to total hip replacement. Where pre-existing osteoarthritis was already established—reported as Tönnis grade 2–3—results were poor, which fits the broader pattern that diffuse degeneration behaves differently from a contained defect.

Using Liquid Cartilage in the thumb and small joints

Small-joint cartilage problems can feel disproportionately disabling because a tiny worn area can sit in a high-load, high-precision joint. In day-to-day care, options can seem to jump from splints, activity modification and steroid injections to bigger decisions such as fusion or joint replacement.

Functionally, these joints are unforgiving: the cartilage surface area is small, the forces per square millimetre are high, and mechanics matter. In the ankle, a focal osteochondral lesion on the talus can trigger sharp “catching” pain on uneven ground; in the wrist, a small defect can undermine grip strength and confidence with lifting. That is the clinical gap where a joint-preserving, defect-targeted scaffold approach is often discussed—aiming to support repair of a focal damaged area rather than treating the whole joint as “arthritis”.

The most concrete small-joint publication in this packet is a 2025 prospective wrist study in 59 intra-articular distal radius fractures, where ChondroFiller was used to fill small residual cartilage defects (reported as 0.5 to ≤2 mm). In a subgroup that had follow-up arthroscopy, the ChondroFiller-treated wrists had better-looking cartilage on “second look” (median Outerbridge 1.5 vs 3 and ICRS 1 vs 3). Importantly, complications were not increased; fibrous tissue was only reported when defects were overfilled.

For the ankle, evidence includes small case-series work in osteochondral lesions of the talus describing arthroscopic ChondroFiller application as technically feasible with encouraging short-term clinical and imaging outcomes, but with limited numbers and follow-up. That can be a useful signal of biological plausibility in a demanding joint, but it is not yet the same as long-term, comparative proof of durability.

How to decide on treatment and arrange an assessment

Decisions about cartilage treatment usually come down to three practical checks: (1) is this a focal defect or diffuse arthritis (the latter tends to behave differently, including in hips graded Tönnis 2–3); (2) is there a mechanical problem such as “catching” or locking that may need keyhole work to remove a flap or loose body before any scaffold strategy is considered; and (3) which joint is involved (the evidence base is strongest in the knee and hip, and thinner in many other joints).

The trade-off between a scaffold approach and “bigger” cartilage operations is often about goals and tolerance for procedural burden. ChondroFiller-based approaches are described as single-stage, cell-free scaffold techniques placed into a defined defect; MACI/ACI are cell-based procedures supported by broader mid- to long-term datasets in appropriately selected knee defects, but involve greater surgical and rehabilitation burden.

Where a scaffold approach is discussed, the technical sensitivity matters: published protocols for focal-defect repair emphasise accurate defect targeting/placement and appropriate lesion morphology rather than a “general into-the-joint” shot.

A helpful closing heuristic is this: a scaffold approach may plausibly substitute for some keyhole cartilage work when there is a treatable focal defect and no mechanical blockage driving symptoms, but it is less likely to replace surgery when the problem is diffuse degeneration or a joint that truly “locks”. The remaining uncertainties should be part of the conversation—most notably, the lack of randomised head-to-head trials against MACI/ACI for many scaffold approaches, and the reality that some people still progress to further surgery (including joint replacement) despite scaffold treatment in medium-term follow-up.

1. [1] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y